The growth in the forecast period can be attributed to increasing global immunization initiatives, rising prevalence of vaccine-preventable diseases, expanding healthcare access in emerging economies, supportive government policies and funding, and growing awareness about pediatric immunization. Major trends in the forecast period include advancements in cold chain logistics, integration with digital vaccination tracking systems, innovation in formulations, advancements in vaccine delivery technologies, and advancements in combination vaccines.
The growing number of pertussis cases is expected to drive the growth of the Infanrix and Infanrix-Hexa vaccine market. Pertussis, also known as whooping cough, is a highly contagious respiratory disease, and the prevalence of the condition has been rising due to factors such as lower vaccination rates, changes in immunity, and an increase in undiagnosed or misdiagnosed cases. As pertussis cases rise, the demand for Infanrix and Infanrix-Hexa vaccines increases since these vaccines effectively prevent the disease. For example, in October 2024, the Health Protection Surveillance Centre in Ireland reported 514 pertussis cases, a significant increase from the 18 cases in 2023, and much higher than the 7 cases in 2022 and 5 cases in 2021. This increase in pertussis cases is expected to drive the demand for these vaccines, fueling market growth.
The growth of the Infanrix and Infanrix-Hexa market is also anticipated to be influenced by rising healthcare expenditure. As healthcare spending rises, driven by factors such as an aging population, increasing healthcare needs, advancements in medical technology, and the higher costs of services and medications, more resources are allocated to healthcare services. This increased spending will support immunization efforts, thereby improving vaccine availability and facilitating the growth of the Infanrix and Infanrix-Hexa market. For example, in May 2024, the Office for National Statistics in the UK reported a 5.6% increase in healthcare expenditure from 2022 to 2023, compared to a 0.9% growth in the previous year. This increase in healthcare expenditure is expected to further drive the market for Infanrix and Infanrix-Hexa vaccines.
The rising number of child deaths is also expected to contribute to the growth of the Infanrix and Infanrix-Hexa vaccine market. Child death rates refer to the number of children who die under the age of 15 within a specific time frame, and the increase in child mortality is linked to factors such as malnutrition, inadequate healthcare, infectious diseases, poor hygiene, and economic challenges. The Infanrix and Infanrix-Hexa vaccines help reduce child mortality by protecting children from multiple life-threatening diseases. For instance, in May 2024, the Office for National Statistics reported that there were 2,349 infant deaths and 1,019 child deaths in 2022, an increase from the previous year’s numbers. As child mortality rates rise, the demand for vaccines such as Infanrix and Infanrix-Hexa is expected to increase, driving market growth.
The key company operating in the infanrix and infanrix-hexa market is GlaxoSmithKline plc.
North America was the largest region in the infanrix and infanrix-hexa market in 2024. The regions covered in infanrix and infanrix-hexa report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the infanrix and infanrix-hexa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Infanrix and Infanrix-hexa are vaccines designed to protect infants and young children from several serious infectious diseases. Infanrix is a vaccine that provides protection against diphtheria, tetanus, and whooping cough (pertussis), and is administered in multiple doses starting at 2 months of age to help prevent these infections. In contrast, Infanrix-hexa is a combination vaccine that provides protection against six diseases: diphtheria, tetanus, whooping cough, polio, hepatitis B, and Haemophilus influenzae type b (Hib).
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary patient demographics for Infanrix and Infanrix-hexa include infants, children, adolescents, and adults. Infants, referring to children under 1 year of age, are particularly protected by these vaccines, which prevent multiple infectious diseases. These vaccines are used for clinical indications such as diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis, and Haemophilus influenzae type b (Hib). They are distributed through various channels including hospitals, clinics, public health programs, and pharmacies, with applications in primary vaccination, booster doses, and in combination with other vaccines.
The infanrix and infanrix-hexa market consists of sales of Infanrix vaccines for diphtheria, tetanus, and whooping cough, Infanrix-hexa vaccines for diphtheria, tetanus, whooping cough, polio, hepatitis B, and Haemophilus influenzae type b and combination vaccines for infants and young children to protect against multiple infectious diseases. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Infanrix And Infanrix-hexa Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on infanrix and infanrix-hexa market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for infanrix and infanrix-hexa ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The infanrix and infanrix-hexa market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Patient Demographics: Infants; Children; Adolescents And Adults2) By Clinical Indication: Diphtheria; Tetanus; Pertussis (Whooping Cough); Hepatitis B; Poliomyelitis; Haemophilus Influenzae Type B (Hib)
3) By Distribution Channel: Hospitals; Clinics; Public Health Programs; Pharmacies
4) By Application: Primary Vaccination; Booster Doses; Combination With Other Vaccines
Key Companies Profiled: GlaxoSmithKline plc
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- GlaxoSmithKline plc